Baseline characteristics of the enrolled patients
| . | Patients, N = 355 . | D-d normal at T0 or at T30, N = 243 . | D-d abnormal at T0 or at T30, N = 104 . | P* . |
|---|---|---|---|---|
| Female sex, n (%) | 162 (45.6) | 107 (44) | 53 (51) | .28 |
| Age | ||||
| Mean ± 95% CI, y | 62 + 1.2 | 59 + 2 | 69 + 2 | < .001 |
| 65 y or older, n (%) | 195 (55) | 108 (44.4) | 78 (75) | < .001 |
| Type of venous thromboembolism, n (%) | ||||
| Proximal DVT; no PE | 236 (66.5) | 155 (63.7) | 73 (70.2) | .22 |
| DVT + symptomatic PE | 43 (12.1) | 30 (12.3) | 13 (12.5) | .97 |
| Isolated PE | 76 (21.4) | 58 (23.8) | 18 (17.3) | .22 |
| Comorbidities | 155 (43.7) | 97 (39.9) | 57 (54.8) | .014 |
| Residual venous thrombosis, n (%) | 124 (35) | 84 (40.2) | 42 (44.2) | .59 |
| (no. CUS available, %) | (302; 85) | (209; 86) | (95; 91.3) | |
| Congenital thrombophilic alteration, n (%) | ||||
| Examined, n (%) | 273 (77) | 206 (84.8) | 67 (64.4) | |
| All | 132 (48.3) | 97 (47.1) | 36 (53.7) | .42 |
| Prot C, S, AT deficiencies, LAC | 5 (1.8) | 2 (1.0) | 3 (4.4) | .18 |
| Hyperhomocysteinemia | 60 (22) | 43 (20.1) | 18 (26.8) | .39 |
| FV Leiden | 33 (12) | 25 (12.3) | 8 (11.9) | .96 |
| Prothrombin mutation | 20 (7.3) | 16 (7.7) | 4 (6.0) | .82 |
| Combined alterations and/or homozygous | 14 (5.1) | 11 (5.3) | 3 (4.5) | .78 |
| Duration of previous anticoagulant treatment, n (%) | ||||
| Less than 6 months, n (%) | 77 (21.6) | 54 (22.2) | 21 (20.2) | .78 |
| 7 to 12 months, n (%) | 164 (46.2) | 110 (45.2) | 49 (47.1) | .84 |
| More than 12 months, n (%) | 114 (32.1) | 79 (32.5) | 34 (32.7) | .97 |
| Total duration of follow-up, patient y | 365 | 212 | 153 | < .001 |
| Follow-up, mean ± 95% CI, mo | 10.6 ± 0.2 | 18 ± 16 |
| . | Patients, N = 355 . | D-d normal at T0 or at T30, N = 243 . | D-d abnormal at T0 or at T30, N = 104 . | P* . |
|---|---|---|---|---|
| Female sex, n (%) | 162 (45.6) | 107 (44) | 53 (51) | .28 |
| Age | ||||
| Mean ± 95% CI, y | 62 + 1.2 | 59 + 2 | 69 + 2 | < .001 |
| 65 y or older, n (%) | 195 (55) | 108 (44.4) | 78 (75) | < .001 |
| Type of venous thromboembolism, n (%) | ||||
| Proximal DVT; no PE | 236 (66.5) | 155 (63.7) | 73 (70.2) | .22 |
| DVT + symptomatic PE | 43 (12.1) | 30 (12.3) | 13 (12.5) | .97 |
| Isolated PE | 76 (21.4) | 58 (23.8) | 18 (17.3) | .22 |
| Comorbidities | 155 (43.7) | 97 (39.9) | 57 (54.8) | .014 |
| Residual venous thrombosis, n (%) | 124 (35) | 84 (40.2) | 42 (44.2) | .59 |
| (no. CUS available, %) | (302; 85) | (209; 86) | (95; 91.3) | |
| Congenital thrombophilic alteration, n (%) | ||||
| Examined, n (%) | 273 (77) | 206 (84.8) | 67 (64.4) | |
| All | 132 (48.3) | 97 (47.1) | 36 (53.7) | .42 |
| Prot C, S, AT deficiencies, LAC | 5 (1.8) | 2 (1.0) | 3 (4.4) | .18 |
| Hyperhomocysteinemia | 60 (22) | 43 (20.1) | 18 (26.8) | .39 |
| FV Leiden | 33 (12) | 25 (12.3) | 8 (11.9) | .96 |
| Prothrombin mutation | 20 (7.3) | 16 (7.7) | 4 (6.0) | .82 |
| Combined alterations and/or homozygous | 14 (5.1) | 11 (5.3) | 3 (4.5) | .78 |
| Duration of previous anticoagulant treatment, n (%) | ||||
| Less than 6 months, n (%) | 77 (21.6) | 54 (22.2) | 21 (20.2) | .78 |
| 7 to 12 months, n (%) | 164 (46.2) | 110 (45.2) | 49 (47.1) | .84 |
| More than 12 months, n (%) | 114 (32.1) | 79 (32.5) | 34 (32.7) | .97 |
| Total duration of follow-up, patient y | 365 | 212 | 153 | < .001 |
| Follow-up, mean ± 95% CI, mo | 10.6 ± 0.2 | 18 ± 16 |
D-d denotes D-dimer; VKA, vitamin K antagonist treatment; FV Leiden, factor V Leiden mutation; DVT, deep vein thrombosis; PE, pulmonary embolism; AT, antithrombin; LAC, lupus anticoagulant; and CUS, compression ultrasonography.
P value refers to χ2 or Fisher exact test or t test, as appropriate, between normal D-d and abnormal D-d.